The Panel's charter was also amended on November 6, 2014 (80 FR 23009), and the number of members was revised from up to 19 to up to 15 members
Given the FDAs April 2025 alert, informed consent for compounded topical finasteride should cover systemic absorption risk, known side effects (sexual, neuropsychiatric), transfer risk to household members (especially women of childbearing age), and the non-FDA-approved status of the formulation
In addition, future clinical studies should give greater attention to prospective, multicenter, and long-term follow-up clinical studies
The refusal to provide this essential treatment a day early, when the patient is symptomatic, is fundamentally different from a dietary suggestion
PMID: 30546248 4 Carnitine Deficiency in Chinese Children with Epilepsy on Valproate Monotherapy